Top Story

Angelina Jolie effect appears to have long-term impact on prophylactic mastectomy use

November 25, 2015

More women with BRCA1 mutations are inquiring about and undergoing double prophylactic mastectomies since Angelina Jolie publicly announced that she had the preventive procedure in May 2013, according to a letter written in Breast Cancer Research.

D. Gareth Evans, MD, FCRP, professor of medical genetics and epidemiology at University of Manchester in the U.K. and at the Genesis Prevention Centre Family History clinic, and colleagues followed up on previously published research that identified a 2.5-fold increase in the amount of referrals for a bilateral risk-reducing mastectomy among British women with a family history of breast cancer in first the 4 months following Jolie’s announcement.


Personalized T-cell therapy yields promising outcomes in relapsed, refractory CLL

HemOnc Today, November 23, 2015
Chimeric antigen receptor T-cell therapy produced durable responses in patients with relapsed and refractory chronic lymphocytic leukemia, according to the results of a…
Cover StoryPublication Exclusive

VTE risk in patients with cancer often overlooked understudied

HemOnc Today, November 23, 2015
Amid the myriad concerns that accompany a cancer diagnosis, the risk for venous thromboembolism may be last on the minds of patients and clinicians.However, substantial…
EditorialPublication Exclusive

Peto's paradox: Elephants, whales, Chihuahuas and cancer

HemOnc Today, November 23, 2015
Derek Raghavan, MD, PhD
We have long been fascinated by the relationship between oncogenesis and ontogenesis, the factors that influence both, and the potential “reversibility” of…
Drug PipelinePerspectivePublication Exclusive

Hematology Drugs in the Pipeline

HemOnc Today, November 23, 2015
HemOnc Today presents the most recent information about hematology drugs in the pipeline. Drugs listed here are in phase 2 or phase 3 development for a variety of…
More News Headlines »

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Meeting News Coverage Video

VIDEO: Prognostic models can have ‘tremendous impact’ on long-term outcomes in CLL

November 20, 2015
More »

The Patient with Pancreatic Cancer

No commercial support for this activity.

Pancreatic cancer only accounts for 3% of cancer cases, but it is the fourth leading cause of cancer-related death…
More »
Current Issues
View the Current Issue
HemOnc Today